Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.59 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272194 | 1.00 | CACNA1H (0.59) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL4272190 | 1.00 | CACNA1H (0.59) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL4272155 | 0.92 | CACNA1H (0.68) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL7800032 | 0.92 | CACNA1H (0.68) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL4272154 | 0.92 | CACNA1H (0.68) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL7794067 | 0.86 | CACNA1H (0.56) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL4284187 | 0.86 | CACNA1H (0.56) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL4284181 | 0.86 | CACNA1H (0.56) | CACNA1HCACNA1ICACNA1GMCHR1KCNH2 | |
| SCHEMBL4279435 | 0.83 | CACNA1I (0.69) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL4270199 | 0.82 | CACNA1H (0.69) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009146539-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-12-10 | — | — | WO | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNA1H | CACNA1H 3/4885CACNA1I 2/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.